Finoriq research workspace
Absci Corp (ABSI) Company Overview
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in. Review ABSI filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
- Company
- Absci Corp (ABSI)
- Ticker
- ABSI
- Market Cap
- $1.3B
- Latest Price
- $8.15
- Industry
- Biotech & Pharma
Absci Corp (ABSI) Current Valuation Metrics
Static valuation preview for Absci Corp (ABSI). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 901x | Revenue | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -7.2% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -5.9% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 9.62x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.